AYR-A:CA:CNSX-Ayr Wellness Inc (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 2.7

Change

0.00 (0.00)%

Market Cap

USD 0.32B

Volume

0.15M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-30 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
GTII:CA Green Thumb Industries Inc

N/A

USD 3.91B
TRUL:CA Trulieve Cannabis Corp

N/A

USD 2.38B
CL:CA Cresco Labs Inc

N/A

USD 0.75B
PLTH:CA Planet 13 Holdings Inc

N/A

USD 0.22B
AAWH-U:CA Ascend Wellness Holdings Inc.

N/A

USD 0.20B
GRIN:CA Grown Rogue International Inc

N/A

USD 0.20B
IAN:CA iAnthus Capital Holdings Inc

N/A

USD 0.17B
JUSH:CA Jushi Holdings Inc

N/A

USD 0.15B
FFNT:CA 4Front Ventures Corp

N/A

USD 0.10B
MRMD:CA MariMed Inc.

N/A

USD 0.10B

ETFs Containing AYR-A:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.11% 64% D 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.11% 64% D 66% D+
Trailing 12 Months  
Capital Gain 134.78% 90% A- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 134.78% 90% A- 93% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -14.46% 64% D 52% F
Dividend Return -14.46% 64% D 52% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 90.42% 22% F 21% F
Risk Adjusted Return -15.99% 71% C- 62% D
Market Capitalization 0.32B 97% N/A 99% N/A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector